Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

UPDATE 1-British vaccine science chief says: earlier booster campaign wouldn't have been right

Tue, 14th Dec 2021 11:22

(Adds details)

LONDON, Dec 14 (Reuters) - The chair of Britain's vaccine
group said on Tuesday that calling an earlier and faster
COVID-19 vaccine booster campaign would not necessarily have
been the right policy given the scientific evidence at the time.

Britain is racing to offer all adults a booster by the end
of the year as the country faces what Prime Minister Boris
Johnson has termed a "tidal wave" of Omicron variant infections.

Asked if in retrospect it would have been better to have an
earlier booster campaign to protect against a new variant,
Professor Lim Wei Shen, chair for COVID-19 immunisation on the
government's Joint Committee on Vaccination and Immunisation,
said: "The simple answer is no.

"The decision in September to offer vaccination to people
over 50 for example was based on the Delta variant, which was
circulating and the waning of protection against severe
disease."

He said the committee had decided to accelerate the booster
campaign on Nov. 29, three days after WHO declared Omicron a
variant of concern.

"We could have potentially called it earlier - two days
earlier - but I don't think we could call it before it was
identified," he said.

Lim also told the committee of lawmakers that the country
could have moved earlier to vaccinate children aged between 12
and 15 if it had had the benefit of extra data on safety.

He said shots could be offered to children as young as five.

"We are discussing that at the moment," he said. "We're also
waiting for the vaccines to be approved by MHRA."

Lim said the decision could be made before Christmas.
(Reporting by Guy Faulconbridge and Paul Sandle)

Related Shares

More News
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslode...

18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with infla...

18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with pacl...

17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "impo...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.